{
    "2019-03-14": [
        [
            {
                "time": "2018-11-15",
                "original_text": "Roche Receives EC Approval for Label Expansion of Hemlibra",
                "features": {
                    "keywords": [
                        "Roche",
                        "EC Approval",
                        "Label Expansion",
                        "Hemlibra"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-11-16",
                "original_text": "Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades",
                "features": {
                    "keywords": [
                        "Blue Chip",
                        "Drug Stocks",
                        "Reckoning",
                        "Downgrades"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-17",
                "original_text": "Novartis generics boss quits amid conjecture over business's future",
                "features": {
                    "keywords": [
                        "Novartis",
                        "generics",
                        "boss quits",
                        "conjecture",
                        "business's future"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "generic drugs"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-18",
                "original_text": "[$$] Head of Novartis generic drugs business steps down",
                "features": {
                    "keywords": [
                        "Novartis",
                        "generic drugs",
                        "steps down"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "generic drugs"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}